← back to search

Clovis Adam

Sorbonne Université · FR
Area of research
Neurology · Genetics
Research interest
Research interests include Glioma Diagnosis and Treatment, Amyloidosis: Diagnosis, Treatment, Outcomes, Peripheral Neuropathies and Disorders, and CNS Lymphoma Diagnosis and Treatment.
h-index
26
citations
2,691
works
147
NIH funding
primary concept
Medicine
email

Recent publications

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma
Journal of Clinical Oncology 2024cited by 27position: middledoi
CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas
Acta Neuropathologica Communications 2024cited by 10position: middledoi
Molecular and clinical diversity in primary central nervous system lymphoma
Annals of Oncology 2022cited by 81position: middledoi
Rosette‐forming glioneuronal tumours are midline, <i>FGFR1</i>‐mutated tumours
Neuropathology and Applied Neurobiology 2022cited by 15position: middledoi
Molecular and clinical diversity in primary central nervous system lymphoma: a LOC Network study
Research Square 2022cited by 1position: middledoi
Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients
Autoimmunity Reviews 2021cited by 9position: middledoi
Clinical Characteristics and Long-term Surgical Outcome of Spinal Myxopapillary Ependymoma: A French Cohort of 101 Patients
Research Square 2021cited by 0position: middledoi
Biodegraded magnetosomes with reduced size and heating power maintain a persistent activity against intracranial U87-Luc mouse GBM tumors
Journal of Nanobiotechnology 2019cited by 28position: middledoi
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study
Neuro-Oncology 2019cited by 16position: middledoi
Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate model
Journal of neurosurgery 2016cited by 122position: middledoi
Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas
Nature Communications 2016cited by 112position: middledoi
Mutational analysis of primary central nervous system lymphoma
Oncotarget 2014cited by 182position: middledoi
Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits
Journal of neurosurgery 2013cited by 61position: middledoi
Recurrent Mutations of <i>MYD88</i> and <i>TBL1XR1</i> in Primary Central Nervous System Lymphomas
Clinical Cancer Research 2012cited by 239position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Dominique Figarella‐Branger · Centre National de la Recherche Scientifique2 papers (2014–2022)Franck Bielle · Centre National de la Recherche Scientifique2 papers (2021–2022)Jean‐Yves Chapelon · Université Claude Bernard Lyon 12 papers (2013–2016)Cyril Lafon · Université Claude Bernard Lyon 12 papers (2013–2016)Karima Mokhtari · NeurON : Interface Neuro-machine2 papers (2014–2022)Michael Canney · Centre d'Énergétique et de Thermique de Lyon2 papers (2013–2016)Ahmed Idbaïh · Institut de Myologie2 papers (2019–2021)Alexandre Carpentier · Sorbonne Université2 papers (2013–2016)Marc Polivka · Hôpital Lariboisière2 papers (2014–2021) · 1 papers (2021–2021)Audrey Rousseau · Hospices Civils de Lyon1 papers (2022–2022)Sandrine Eimer · Institut de Génomique Fonctionnelle1 papers (2014–2014)Luc Mouthon · Ministere de l'Education Nationale1 papers (2021–2021) · 1 papers (2022–2022)David Meyronet · Université Claude Bernard Lyon 11 papers (2022–2022)Catherine Godfraind · Peuplements végétaux et bioagresseurs en milieu tropical1 papers (2022–2022)Khê Hoang‐Xuan · County Hospital1 papers (2014–2014) · 1 papers (2019–2019)Marie Théaudin · University of Lausanne1 papers (2021–2021)Carole Colin · Centre National de la Recherche Scientifique1 papers (2022–2022)